The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin

被引:21
|
作者
Yamaguchi, Tetsuo [1 ]
Konishi, Hiroe [1 ,2 ]
Aoki, Kotaro [1 ]
Ishii, Yoshikazu [1 ]
Chono, Koji [3 ]
Tateda, Kazuhiro [1 ]
机构
[1] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[2] Toho Univ, Grad Sch Med, Div Pediat, Tokyo, Japan
[3] Astellas Pharma Inc, Res Portfolio Planning Drug Discovery & Res, Tsukuba, Ibaraki, Japan
关键词
16S rRNA; Clostridioides difficile; Fidaxomicin; Microbiota; RIBOTYPE; 027; MOUSE MODEL; INFECTION; LACTOFERRIN; STRAIN; SUSCEPTIBILITY; EPIDEMIOLOGY; RECURRENCE; PREVENTION; OUTCOMES;
D O I
10.1016/j.jiac.2019.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To investigate the effect of vancomycin and fidaxomicin on the diversity of intestinal microbiota in a mouse model of Clostridioides difficile infection. Methods: Mice were divided into 11 models (4 mice per model): 6 uninoculated models and 5 models inoculated with C. difficile BI/NAP1/027. Inoculated models were prepared using intraperitoneal clindamycin followed by inoculation with C. difficile BI/NAP1/027. Uninoculated and C. difficile-inoculated mice received 2 or 7 days' vancomycin or fidaxomicin. Clostridium butyricum MIYAIRI 588 probiotic and lactoferrin prebiotic were administered for 10 days to uninoculated mice. Intestinal microbiome composition was investigated by sequence analyses of bacterial 16S rRNA genes from faeces, and microbiota diversity estimated. Results: In uninoculated, untreated ('normal') mice, Clostridia (57.8%) and Bacteroidia (32.4%) accounted for the largest proportions of gut microbiota. The proportion of Clostridia was numerically reduced in C. difficile-inoculated versus normal mice. Administration of vancomycin to C. difficile-inoculated mice reduced the proportions of Bacteroidia and Clostridia, and increased that of Proteobacteria. Administration of fidaxomicin to C. difficile-inoculated mice reduced the proportion of Clostridia to a lesser extent, but increased that of Bacteroidia. Microbiota diversity was lower in C. difficile-inoculated versus normal mice (164.5 versus 349.1 operational taxonomic units (OTUs), respectively); treatment of C. difficile-inoculated mice with 7 days' vancomycin reduced diversity to a greater extent than did 7 days' fidaxomicin treatment (26.2 versus 134.2 OTUs, respectively). Conclusions: Both C. difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin. (c) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:483 / 491
页数:9
相关论文
共 50 条
  • [41] The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice
    Tomkovich, Sarah
    Stough, Joshua M. A.
    Bishop, Lucas
    Schloss, Patrick D.
    MSPHERE, 2020, 5 (05)
  • [42] The impact of ibezapolstat and other Clostridioides difficile infection-relevant antibiotics on the microbiome of humanized mice
    Wolfe, Trenton M.
    Jo, Jinhee
    Pinkham, Nick V.
    Garey, Kevin W.
    Walk, Seth T.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (04)
  • [43] Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non-C. difficile diarrhea, and C. difficile-colonized patients
    Vazquez-Cuesta, Silvia
    Villar, Laura
    Lozano Garcia, Nuria
    Fernandez, Ana I.
    Olmedo, Maria
    Alcala, Luis
    Marin, Mercedes
    Munoz, Patricia
    Bouza, Emilio
    Reigadas, Elena
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
  • [44] Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to Clostridioides difficile
    Patel, Nimish
    Lowry, Colleen
    Morgenson, Daralyn
    Shah, Vaishali
    Stornelli, Nicholas
    Lodise, Thomas P.
    PHARMACOTHERAPY, 2021, 41 (02): : 212 - 219
  • [45] Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure
    Chilton, C. H.
    Crowther, G. S.
    Freeman, J.
    Todhunter, S. L.
    Nicholson, S.
    Longshaw, C. M.
    Wilcox, M. H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (02) : 451 - 462
  • [46] Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of Clostridioides difficile colonization in mice
    Pearlmutter, Basya S.
    Carlisle, Matthew G.
    Wilson, Brigid M.
    Sangwan, Naseer
    Donskey, Curtis J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (01)
  • [47] Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE)
    Wolf, Joshua
    Kalocsai, Krisztina
    Fortuny, Claudia
    Lazar, Stefan
    Bosis, Samantha
    Korczowski, Bartosz
    Petit, Arnaud
    Bradford, Daniel
    Croos-Dabrera, Rodney
    Incera, Elodie
    Melis, Joost
    van Maanen, Rob
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (10) : 2581 - 2588
  • [48] An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections
    Rao, Krishna
    Zhao, Qianzi
    Bell, Justin
    Krishnan, Jay
    Henig, Oryan
    Daniel, Jolene
    Sawaya, Kara
    Albin, Owen
    Mills, John P.
    Petty, Lindsay A.
    Gregg, Kevin
    Kaul, Daniel
    Malani, Anurag N.
    Pogue, Jason
    Kaye, Keith S.
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (02) : 277 - 282
  • [49] Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin
    Sambol, Susan P.
    Skinner, Andrew M.
    Serna-Perez, Fidel
    Owen, Benjamin
    Gerding, Dale N.
    Johnson, Stuart
    MICROBIOLOGY SPECTRUM, 2023, 11 (02)
  • [50] Identification of novel p-cresol inhibitors that reduce Clostridioides difficile's ability to compete with species of the gut microbiome
    Harrison, Mark A.
    Farthing, Rebecca J.
    Allen, Nyasha
    Ahern, Lucy M.
    Birchall, Kristian
    Bond, Michael
    Kaur, Harparkash
    Wren, Brendan W.
    Bergeron, Julien R. C.
    Dawson, Lisa F.
    SCIENTIFIC REPORTS, 2023, 13 (01)